SCHEMBL3099146

SCHEMBL3099146

CCc1c(C)ccc2[nH]c(C(=O)O)cc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 3/20 0.51
CYP1A2 P05177 2/20 0.51
PRNP P04156 1/20 0.51
CYP2C9 P11712 1/20 0.51
PPARG P37231 1/20 0.51
HIF1A Q16665 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
RXFP1 Q9HBX9 1/20 0.51
NR2E3 Q9Y5X4 1/20 0.51
NCOR2 Q9Y618 1/20 0.51
KDM4E B2RXH2 4/20 0.49
ALDH1A1 P00352 4/20 0.49
HSD17B10 Q99714 4/20 0.49
LMNA P02545 2/20 0.49
PIN1 Q13526 1/20 0.47
NGFR P08138 1/20 0.44
MEN1 O00255 2/20 0.44
GAA P10253 2/20 0.44
KMT2A Q03164 2/20 0.44
HPGD P15428 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22394977 0.83 CYP2C19 (0.50) CYP2C19CYP1A2PRNPCYP2C9PPARG
SCHEMBL3107966 0.80 ALDH1A1 (0.54) CYP2C19CYP1A2KDM4EALDH1A1HSD17B10
SCHEMBL8911576 0.79 KDM4E (0.53) CYP2C19CYP1A2KDM4EALDH1A1HSD17B10
SCHEMBL11737870 0.78 KDM4E (0.49) CYP2C19CYP1A2KDM4EALDH1A1HSD17B10
SCHEMBL11744575 0.78 KDM4E (0.51) CYP2C19CYP1A2KDM4EALDH1A1HSD17B10
SCHEMBL11740631 0.78 KDM4E (0.51) CYP2C19CYP1A2CYP2C9KDM4EALDH1A1
SCHEMBL11742020 0.77 PLA2G4A (0.44) CYP2C19CYP1A2CYP2C9KDM4EALDH1A1
SCHEMBL25724136 0.75 HSD17B10 (0.42) CYP2C19CYP1A2PRNPCYP2C9PPARG
SCHEMBL14208058 0.74 DAO (0.58) CYP2C19CYP1A2KDM4EALDH1A1HSD17B10
SCHEMBL8913109 0.74 SRD5A2 (0.63) CYP2C19CYP1A2CYP2C9NPSR1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8071622-B2 1-[1-(6-Methoxy-1H-indole-2-carbonyl)-piperidin-4-yl]-1,3-dihydro-benzoimidazol-2-one; vasopressin receptors antagonist; antidepressant, anxiolytic agent; dysmenorrhea, hypertension, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder HOFFMAN-LA ROCHE INC. (US) 2011-12-06 US disclosed
US-7799923-B2 Vasopressin receptor antagonists; (4-Benzotriazol-1-yl-piperidin-1-yl)-(5-chloro-1H-indol-2-yl)-methanone; antidepressants, anxiolytic agents; dysmenorrhea, hypertension, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder HOFFMANN-LA ROCHE INC. (US) 2010-09-21 US disclosed
EP-2089381-B1 INDOLES WHICH ACT AS VIA RECEPTOR ANTAGONISTS HOFFMANN LA ROCHE (CH) 2010-06-30 EP disclosed
CN-101541786-A Indoles as V1a receptor antagonists HOFFMANN LA ROCHE (CH) 2009-09-23 CN disclosed
EP-2089381-A1 INDOLES WHICH ACT AS VIA RECEPTOR ANTAGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2009-08-19 EP disclosed
US-20080269290-A1 Indoles F. HOFFMANN-LA ROCHE AG (CH) 2008-10-30 US disclosed
US-20080139618-A1 INDOLES HOFFMAN-LA ROCHE INC. 2008-06-12 US disclosed
US-20080139548-A1 INDOLES F. HOFFMANN-LA ROCHE AG (CH) 2008-06-12 US disclosed
WO-2008068184-A1 INDOLES WHICH ACT AS VIA RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2008-06-12 WO disclosed
US-20080139617-A1 INDOLES HOFFMAN-LA ROCHE INC. 2008-06-12 US disclosed
US-4060626-A Indole-carboxylic carbon compounds and pharmaceutical compositions containing them BOEHRINGER MANNHEIM G.M.B.H. (DT) 1977-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080139548-A1 INDOLES HTR1A, AVPR1A, TPH1 CYP2C19 244/4885CYP1A2 210/4885PRNP 1687/4885
US-20080139617-A1 INDOLES HTR1A, AVPR1A, TPH1 CYP2C19 244/4885CYP1A2 210/4885PRNP 1687/4885
US-20080269290-A1 Indoles HTR1A, AVPR1A, TPH1 CYP2C19 244/4885CYP1A2 210/4885PRNP 1687/4885
US-20080139618-A1 INDOLES HTR1A, AVPR1A, TPH1 CYP2C19 244/4885CYP1A2 210/4885PRNP 1687/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.